Our FSP team is seeking Project Managers/Sr. Project Managers to join our growing team. This role requires 2-5+ years of global project management experience, with experience in Oncology or Ophthalmology. Candidates must be based in the United States.

Job Overview:

At times working under the direction of a Project Director, the Senior Project Manager oversees and manages domestic, regional and/or global projects. Responsibilities typically include developing and managing project teams, communications, risk, scope, schedule, cost, quality, and stakeholders, effectively ensuring that variance from plan is proactively and effectively mitigated and client expectations are met. The Senior Project Manager is expected to have a working knowledge of drug development and clinical trial execution. They also compile and drive documentation for the project, ensuring the accuracy and quality of regulatory data. The Senior Project Manager may also have line management and / or business development responsibilities.

Summary of Responsibilities:

Operational delivery.
Accountable for project delivery with regards to agreed time, scope, cost, and quality.
TEAM COMMUNICATION: Serve as key client contact for assigned projects, establishing working relationships with client project teams which result in client satisfaction, operational excellence and thereby increase potential for repeat business.
Lead core project team(s) and facilitate team's ability to lead extended project team(s), ensuring effective cross-functional teamwork among project team members including both internal and external stakeholders. Depending on size and scope of project(s), this job duty may be performed in collaboration with a Project Director.
Serve as escalation point for project issues to internal and external stakeholders, as appropriate.
TEAM COMMUNICATION: Proactively identify and resolve conflicts as needed.
COST: Understand the project delivery strategy, costing assumptions and resulting budget for assigned project(s).
SCOPE: Deliver project(s) to scope, schedule, and costs, ensuring all remain on track with the contract and with financial performance targets. Initiate and implement appropriate actions to proactively manage the change control process both internally and externally.
RISK: Proactively lead both quality control and risk assurance activities to ensure project deliverables are met according to regulatory, Fortrea and client requirements.
QUALITY: Create and manage variance to required project plans. Per SOPs, implement and monitor progress against project plans and revise, as necessary. Ensure that all staff allocated to assigned project(s) adheres to professional standards and SOPs, providing performance feedback to team member’s respective supervisors.
Aid in development and maintenance of key project performance indicators for client specified metrics, ensuring that the KPIs are within scope of the project contract.
Define and manage project resource needs and establish succession plans for key resources.
Business Development.
In collaboration with relevant departments, prepare and deliver presentations for new business as required.
Perform other duties as assigned by management.
Line Management and Talent Development.
Trains and mentors PM Academy PCs in multiple areas of expertise.
May be responsible for Line Management and Talent Development.
Ensures allocated resources are aligned with current and forecasted work in terms of capability, quantity, timing, and efficiency.
May be responsible for on-boarding, development, and retention of high performing talent; strengthening and deepening talent bench and succession.
Assesses project management competencies for assigned staff in order to create developmental plans that will increase competencies and close performance gaps.
Provides line management and technical support to assigned project leaders, including training, development, and performance review of assigned staff.
All other duties as needed or assigned.

Qualifications (Minimum Required):

University/college degree (life science preferred) or certification in a related allied health profession (i.e., nursing, medical or laboratory technology) from an appropriately accredited institution.
Fortrea may consider relevant and equivalent experience in lieu of educational requirements.

Experience (Minimum Required):

Minimum of seven (7) years of relevant clinical research experience in a pharmaceutical company/CRO, including at least two (2) years of full project management responsibility.
Working knowledge of ICH Guidelines and GCP including international regulatory requirements for the conduct of clinical development programs.
Advanced computer skills (e.g., Microsoft Word, Excel, Project, Access, and Power Point).
Experience managing projects in a matrix and virtual environment.
Excellent communication, planning, and organizational skills.
Demonstrated ability to lead by example and to encourage team members to seek solutions independently.
Demonstrated ability to handle multiple competing priorities and to utilize resources effectively.
Demonstrated ability to inspire effective teamwork and motivate staff within a matrix system.
Financial awareness and ability to actively utilize financial tracking systems.
Good knowledge of project management processes.
Ability to work independently and mentor junior project team members.
Ability to negotiate and liaise with clients in a professional manner.
Ability to present to staff at all levels.
Oncology or Ophthalmology experience

Preferred Qualifications Include:

Master’s or other advanced degree
PMP certification
Biotech experience

What do you get?

Regular, full-time or part-time employees working 20 or more hours per week are eligible for comprehensive benefits including but not limited to:

Medical, Dental, Vision, Life, STD/LTD (multiple insurance carriers)
401(K)
Paid time off (PTO) – Flex Plan
Employee recognition awards
Multiple ERG’s (employee resource groups)
Target Pay Range (based on title of PM II or Sr. PM): $140-185K

#LI - Remote

Applications will be accepted on an ongoing basis.

Work Environment:

Work is performed in an office environment with exposure to electrical office equipment.
30% travel

Physical Requirements:

Ability to sit for extended periods and operate a vehicle safely.
Repetitive hand movement of both hands with the ability to make fast, simple, repeated movements of the fingers, hands, and wrists.
Occasional crouching, stooping, with frequent bending and twisting of upper body and neck.
Ability to access and use a variety of computer software developed both in-house and off-the-shelf.
Light to moderate lifting and carrying (or otherwise moves) objects including luggage and laptop computer with a maximum lift of 15-20 lbs.
Regular and consistent attendance.
Varied hours may be required.

Learn more about our EEO & Accommodations request here.

About the company

Fortrea is a global contract research organization that provides clinical development services for the life sciences industry. It offers full service, functional service, and hybrid outsourcing models across Phase I–IV trials, clinical pharmacology, and consulting, serving biotech, biopharma, medical devices, and diagnostics. Its work is delivered through a network of investigators and specialized teams in approximately 100 countries, supporting trial design, execution, data management, and regulatory compliance. Fortrea’s approach combines its legacy experience from Covance and Labcorp with a pureplay CRO model to deliver fit-for-purpose solutions and agile project delivery. This positions it to manage trials across more than 20 therapeutic areas with scientific rigor and operational excellence. The company aims to bring predictability to clinical trial execution and help clients turn research ideas into real-world outcomes.

Company Size

10,001+

Company Stage

IPO

Headquarters

Winston-Salem, NC

Founded

2023

Get referred to Fortrea

See people who can refer or advise you

Simplify's Take

What believers are saying

Q2 2026 revenue beat estimates at $678.2 million, lifting full-year guidance.
Book-to-bill hit 1.06x in Q2, signaling improving demand after biotech recovery.
Knoblauch returned September 9, 2026, restoring dedicated CFO leadership after litigation.

What critics are saying

Fortrea's revenue still fell 4.5% in Q2, exposing fragile organic growth.
FSP headwinds continue, and management cited flat second-half performance after Q2.
Another CFO lawsuit or compliance dispute shatters buyer trust across Fortrea's pipeline.

What makes Fortrea unique

Fortrea owns early-phase capabilities after buying Worldwide's CPU and bioanalytical lab in Texas.
Its 100-country footprint and 20-therapeutic-area depth support global multicenter trials.
Three decades of clinical development experience gives Fortrea credibility with biopharma sponsors.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
401(k) Retirement Plan
401(k) Company Match
Unlimited Paid Time Off
Paid Vacation

Growth & Insights and Company News

6 month growth

27%

1 year growth

27%

2 year growth

27%

The Markets Daily

Nov 1st, 2026

What Fortrea (FTRE) said on its Q3 earnings call.

What Fortrea (FTRE) said on its Q3 earnings call. Fortrea (NASDAQ:FTRE) reported third-quarter 2026 revenue of $691.5 million, down 1.4% from a year earlier but up 2.0% sequentially, as the contract research organization cited improving demand, stronger operational execution and continued cost discipline. Adjusted EBITDA totaled $58.0 million, rising 14.4% from $50.7 million in the prior-year quarter. Adjusted EBITDA margin expanded 120 basis points year over year to 8.4%, though it declined 30 basis points sequentially from approximately 8.7% in the second quarter. CEO Anshul Thakral said the company's return-to-growth strategy is centered on commercial, operational and financial execution. "The market is becoming more supportive, but our progress is not simply a function of market recovery," Thakral said, pointing to changes in the company's go-to-market model and greater coordination across teams. Bookings and backlog adjustment. Fortrea recorded net new business awards of $773 million during the quarter, producing a book-to-bill ratio of 1.12 times, compared with 1.06 times in the second quarter. Its trailing 12-month book-to-bill ratio also stood at 1.12 times. Backlog was $7.3 billion at quarter-end, down from $7.8 billion at the end of the second quarter and $7.6 billion a year earlier. CFO Jason Knoblauch said the company recorded a cumulative $558 million adjustment to backlog to better reflect its estimate of remaining revenue expected from contracts in its portfolio. The adjustment included inactive-study dynamics and what the company internally calls "not to deliver" dynamics, Knoblauch said. He described it as an accumulation of ordinary-course changes in contract scope, including trials that can become inactive over time. The adjustment was not included in reported net book-to-bill and did not affect reported financial results or near- and medium-term revenue planning, according to the company. Cancellations were within normal ranges but were "slightly elevated" during the quarter, Knoblauch said. He added that cancellations and negative contract amendments that closed in the quarter were within one standard deviation of normal levels. Margins, cash flow and balance sheet. Fortrea's year-over-year margin expansion reflected a more favorable portfolio mix and cost-management and efficiency initiatives, which together contributed more than 300 basis points of benefit, Knoblauch said. Those gains were partly offset by increased investments in employee compensation, including incentive compensation. Net income was $0.6 million, compared with a net loss of $15.9 million in the third quarter of 2025 and a $13.2 million loss in the preceding quarter. Adjusted net income was $27.9 million, versus $11.7 million a year earlier. Adjusted diluted earnings per share were $0.28, compared with $0.12 in the prior-year quarter. Operating cash flow was $60.8 million and free cash flow was $52.5 million, improving from $28.9 million and $19.9 million, respectively, in the second quarter. Net days sales outstanding improved to 15 days at Sept. 30, from 20 days at the end of June and 33 days a year earlier. The company ended the quarter with approximately $668 million of available liquidity, no revolver borrowings, gross debt of $1.066 billion and net debt of $845.7 million. Net leverage was 3.9 times, representing an improvement of 1.4 turns over the preceding 12 months, driven by EBITDA growth, debt repayment and cash accumulation. Early-phase acquisition expands capabilities. Fortrea completed its acquisition of the Early Phase Services business from Worldwide Clinical Trials on Oct. 19. The transaction expands the company's clinical pharmacology network to more than 570 beds across the U.S. and U.K. and adds bioanalytical and safety laboratory capabilities. Thakral said the acquired business includes a 200-bed facility in San Antonio, Texas, and a bioanalytical laboratory in Austin. Together with Fortrea's existing Dallas unit, the facilities create a 300-bed Texas network. The Austin laboratory allows Fortrea to perform certain testing internally rather than through third parties, which Thakral said can give the company more control over execution and convert certain pass-through activity into service-fee revenue. The company said the acquired business is expected to be EBITDA-profitable in 2027. Knoblauch said initial integration efforts are focused on commercial activity and incorporating the acquired capabilities into Fortrea's clinical pharmacology services pipeline. Guidance raised and narrowed. Fortrea raised the midpoint and narrowed its full-year outlook. The company now expects 2026 revenue of $2.665 billion to $2.690 billion and adjusted EBITDA of $210 million to $218 million. For the fourth quarter, Knoblauch said the company expects a modest sequential revenue slowdown because the period has fewer working days than the third quarter. He also cited a sequential increase in information-technology operating expense investments as a secondary factor affecting the quarterly outlook. Management did not provide 2027 guidance. Thakral said the company is seeing a recovery in both biotech and biopharma demand, with biotech bookings showing nearly double-digit growth in 2026 and biopharma request-for-proposal activity increasing. He said Fortrea continues to target mid-teens adjusted EBITDA margins over time through revenue growth, portfolio mix, utilization improvements, technology-enabled efficiencies and operating leverage. About Fortrea (NASDAQ:FTRE). Fortrea Holdings Inc is a global contract research organization (CRO) that provides services to pharmaceutical, biotechnology and medical device companies. The company helps clients plan, manage and execute clinical development programs, supporting the testing of new medicines and therapies from early-stage research through regulatory approval and post-approval activities. Its services include Phase I through Phase IV clinical trials, clinical operations, patient recruitment and access, data management, biostatistics, medical monitoring, pharmacovigilance and regulatory support.

Yahoo Finance

Oct 30th, 2026

Fortrea Q3: revenue falls 1.4% to $691.5M, but margin hits 8.4% and guidance midpoint rises

Fortrea Holdings (NASDAQ: FTRE) raised the midpoint of its full-year 2026 revenue and adjusted EBITDA guidance while narrowing both ranges, as it reported third-quarter results on October 29, 2026. Revenue fell 1.4% year-over-year to $691.5 million, mainly because pass-through backlog converted more slowly. Adjusted EBITDA margin rose 120 basis points from a year earlier to 8.4%. The company booked a $558 million backlog adjustment, cutting backlog to $7.3 billion. Free cash flow reached $52.5 million, and net leverage fell to 3.9x. Book-to-bill was 1.12x. Fortrea also completed its purchase of Worldwide Clinical Trials' early phase services business, lifting clinical pharmacology capacity to more than 570 beds. It gave no 2027 guidance.

MarketBeat

Oct 29th, 2026

What Fortrea (FTRE) said on its Q3 earnings call.

What Fortrea (FTRE) said on its Q3 earnings call. October 29, 2026 Key points. * Q3 performance improved: Revenue rose 2.0% sequentially to $691.5 million, while adjusted EBITDA increased 14.4% year over year to $58.0 million, lifting the margin to 8.4%. Net income, adjusted EPS and free cash flow also improved substantially. * Bookings strengthened, but backlog was reduced: Net new business awards reached $773 million, producing a 1.12x book-to-bill ratio. However, Fortrea's backlog fell to $7.3 billion after a cumulative $558 million adjustment for inactive studies and work the company no longer expects to deliver; management said the adjustment does not affect reported results or near-term revenue plans. * Outlook raised and capabilities expanded: Fortrea increased its 2026 outlook to $2.665-$2.690 billion in revenue and $210-$218 million in adjusted EBITDA. Its acquisition of Worldwide Clinical Trials' Early Phase Services business expands its clinical pharmacology network and is expected to become EBITDA-profitable in 2027. * MarketBeat previews the top five stocks to own by November 1st. Fortrea NASDAQ: FTRE reported third-quarter 2026 revenue of $691.5 million, down 1.4% from a year earlier but up 2.0% sequentially, as the contract research organization cited improving demand, stronger operational execution and continued cost discipline. Adjusted EBITDA totaled $58.0 million, rising 14.4% from $50.7 million in the prior-year quarter. Adjusted EBITDA margin expanded 120 basis points year over year to 8.4%, though it declined 30 basis points sequentially from approximately 8.7% in the second quarter. CEO Anshul Thakral said the company's return-to-growth strategy is centered on commercial, operational and financial execution. "The market is becoming more supportive, but our progress is not simply a function of market recovery," Thakral said, pointing to changes in the company's go-to-market model and greater coordination across teams. Bookings and backlog adjustment. Fortrea recorded net new business awards of $773 million during the quarter, producing a book-to-bill ratio of 1.12 times, compared with 1.06 times in the second quarter. Its trailing 12-month book-to-bill ratio also stood at 1.12 times. Backlog was $7.3 billion at quarter-end, down from $7.8 billion at the end of the second quarter and $7.6 billion a year earlier. CFO Jason Knoblauch said the company recorded a cumulative $558 million adjustment to backlog to better reflect its estimate of remaining revenue expected from contracts in its portfolio. The adjustment included inactive-study dynamics and what the company internally calls "not to deliver" dynamics, Knoblauch said. He described it as an accumulation of ordinary-course changes in contract scope, including trials that can become inactive over time. The adjustment was not included in reported net book-to-bill and did not affect reported financial results or near- and medium-term revenue planning, according to the company. Cancellations were within normal ranges but were "slightly elevated" during the quarter, Knoblauch said. He added that cancellations and negative contract amendments that closed in the quarter were within one standard deviation of normal levels. Margins, cash flow and balance sheet. Fortrea's year-over-year margin expansion reflected a more favorable portfolio mix and cost-management and efficiency initiatives, which together contributed more than 300 basis points of benefit, Knoblauch said. Those gains were partly offset by increased investments in employee compensation, including incentive compensation. Discover more Stock Market News Stock Market Holidays Track Stock Market Net income was $0.6 million, compared with a net loss of $15.9 million in the third quarter of 2025 and a $13.2 million loss in the preceding quarter. Adjusted net income was $27.9 million, versus $11.7 million a year earlier. Adjusted diluted earnings per share were $0.28, compared with $0.12 in the prior-year quarter. Operating cash flow was $60.8 million and free cash flow was $52.5 million, improving from $28.9 million and $19.9 million, respectively, in the second quarter. Net days sales outstanding improved to 15 days at Sept. 30, from 20 days at the end of June and 33 days a year earlier. The company ended the quarter with approximately $668 million of available liquidity, no revolver borrowings, gross debt of $1.066 billion and net debt of $845.7 million. Net leverage was 3.9 times, representing an improvement of 1.4 turns over the preceding 12 months, driven by EBITDA growth, debt repayment and cash accumulation. Early-phase acquisition expands capabilities. Fortrea completed its acquisition of the Early Phase Services business from Worldwide Clinical Trials on Oct. 19. The transaction expands the company's clinical pharmacology network to more than 570 beds across the U.S. and U.K. and adds bioanalytical and safety laboratory capabilities. Thakral said the acquired business includes a 200-bed facility in San Antonio, Texas, and a bioanalytical laboratory in Austin. Together with Fortrea's existing Dallas unit, the facilities create a 300-bed Texas network. The Austin laboratory allows Fortrea to perform certain testing internally rather than through third parties, which Thakral said can give the company more control over execution and convert certain pass-through activity into service-fee revenue. The company said the acquired business is expected to be EBITDA-profitable in 2027. Knoblauch said initial integration efforts are focused on commercial activity and incorporating the acquired capabilities into Fortrea's clinical pharmacology services pipeline. Guidance raised and narrowed. Fortrea raised the midpoint and narrowed its full-year outlook. The company now expects 2026 revenue of $2.665 billion to $2.690 billion and adjusted EBITDA of $210 million to $218 million. For the fourth quarter, Knoblauch said the company expects a modest sequential revenue slowdown because the period has fewer working days than the third quarter. He also cited a sequential increase in information-technology operating expense investments as a secondary factor affecting the quarterly outlook. Management did not provide 2027 guidance. Thakral said the company is seeing a recovery in both biotech and biopharma demand, with biotech bookings showing nearly double-digit growth in 2026 and biopharma request-for-proposal activity increasing. He said Fortrea continues to target mid-teens adjusted EBITDA margins over time through revenue growth, portfolio mix, utilization improvements, technology-enabled efficiencies and operating leverage. About Fortrea (NASDAQ:FTRE). Fortrea Holdings Inc is a global contract research organization (CRO) that provides services to pharmaceutical, biotechnology and medical device companies. The company helps clients plan, manage and execute clinical development programs, supporting the testing of new medicines and therapies from early-stage research through regulatory approval and post-approval activities. Its services include Phase I through Phase IV clinical trials, clinical operations, patient recruitment and access, data management, biostatistics, medical monitoring, pharmacovigilance and regulatory support. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider Fortrea, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fortrea wasn't on the list. While Fortrea currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain - combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list. Continue following MarketBeat

Yahoo Finance

Oct 28th, 2026

Fortrea reports Q3 results Thursday as analysts expect revenue to fall 4.3% from $678.2M

Fortrea Holdings (NASDAQ:FTRE), a clinical research company, reports third-quarter results before the bell on Thursday. The market expects revenue to fall 4.3% year on year, against a 3.9% rise in the same quarter last year. Last quarter, Fortrea beat revenue expectations with $678.2 million, down 4.5% year on year, and also beat analysts' EPS estimates. It has missed Wall Street's revenue estimates multiple times over the last two years. Fortrea shares are up 23.2% over the last month, against an average 3.6% gain for its segment. The average analyst price target is $21.71, below the current share price of $24.71. Peers have reported already. Repligen's revenue rose 10.9%, while Medpace's rose 8.5%, in line with estimates.

Financial Post

Oct 22nd, 2026

Fortrea and Omico collaboration to advance biomarker-led oncology drug development.

Fortrea and Omico collaboration to advance biomarker-led oncology drug development. GlobeNewswire Published Oct 22, 2026 Collaboration aims to improve trial planning and expand patient access to biomarker-matched studies in Australia Highlights * Collaboration aims to accelerate precision oncology research in Australia * Combines Fortrea's experience in oncology clinical trials with Omico's Precision Oncology Screening Platform Enabling Clinical Trials (PrOSPeCT) program * Together, Fortrea and Omico offer more efficient investigator site selection and faster patient access by connecting patients with relevant biomarker-driven clinical trials Story continues below This advertisement has not loaded yet, but your article continues below. DURHAM, N.C. and SYDNEY, Oct. 22, 2026 (GLOBE NEWSWIRE) - Fortrea (Nasdaq: FTRE) (the "Company"), a leading global contract research organization ("CRO"), and Omico, Australia's leading precision oncology screening and trial matching organization, today announced a collaboration to accelerate precision oncology research by helping connect cancer patients to biomarker-matched clinical trials. By combining Omico's precision oncology network with Fortrea's scientific and clinical trial experience, the joint effort aims to improve study planning, site selection and patient recruitment to expand access to biomarker-driven oncology research globally. Top Stories Interested in more newsletters? Browse here. Through this initiative, Omico will support Fortrea's clients in their oncology drug development needs by providing access to patient population insights, including genomic profiling, trial-matching capabilities, real-world oncology data and patient referral pathways in Australia, a key country both for early and late phase Oncology clinical research activities. The collaboration will combine Fortrea's oncology drug development experience with Omico's flagship Precision Oncology Screening Platform Enabling Clinical Trials (PrOSPeCT) program, the largest cancer genomics initiative in Australia. PrOSPeCT is designed to provide molecular profiling and help match patients to biomarker-driven clinical trials and targeted therapies. Story continues below "Our collaboration with Omico is about seeking to reach the right patient for the right study as quickly as possible," said Oren Cohen, M.D., Chief Medical Officer at Fortrea. "Modern oncology development demands ever-greater precision to match specific cancers with the therapies most likely to benefit patients, and to do so as quickly as possible. Our work with Omico accelerates our ability to identify the right patients for biomarker-driven studies in Australia and help advance precision medicine for people with cancer." Omico has built one of Australia's most extensive precision oncology ecosystems, combining molecular profiling, real-world evidence, cohort research programs and a nationwide network of investigators and clinical sites. Omico has reported more than 23,000 consented patients within its clinic-genomic databases and has received referrals from more than 1,600 clinicians across Australia. "Australia is well positioned to support global biomarker-driven clinical trials, through Omico's established national precision oncology research infrastructure, expertise and networks," said Professor David Thomas, Chief Science and Strategy Officer at Omico. "By combining our national data and trial matching capabilities with Fortrea's global clinical development expertise, we can help international sponsors identify relevant patient populations, plan trials more effectively and support targeted recruitment." This advertisement has not loaded yet. This advertisement has not loaded yet, but your article continues below. Fortrea's oncology expertise is underpinned by thousands of operational professionals and supported by more than 50 oncology physicians on staff. This collaboration comes at a time when modern oncology drug development has accelerated the focus on precision medicine, biomarker-driven development and targeted patient identification. Working together, Fortrea and Omico can offer more efficient site selection and the ability to match patients with appropriate studies tied to their unique genomic data, enabling more people to participate in studies tailored to their specific condition in Australia. About Fortrea Fortrea (Nasdaq: FTRE) is a leading global provider of clinical development solutions to the life sciences industry. We partner with emerging and large biopharmaceutical, biotechnology, medical device and diagnostic companies to drive healthcare innovation that accelerates life changing therapies to patients. Fortrea provides phase I-IV clinical trial management, clinical pharmacology and consulting services. Fortrea's solutions leverage three decades of experience spanning more than 20 therapeutic areas, a passion for scientific rigor, exceptional insights and a strong investigator site network. Our talented and diverse team working in about 100 countries is scaled to deliver focused and agile solutions to clients globally. Learn more about how Fortrea is streamlining drug development at Fortrea.com and follow us on LinkedIn and X and Bluesky. Story continues below This advertisement has not loaded yet, but your article continues below. About Omico Omico is an independent, national, not-for-profit research organisation changing the way we fight cancer. We work to improve outcomes for Australians with cancer by providing equitable access to precision oncology and translating scientific advances into clinical care and research, and generating the evidence needed to inform health policy and system reform. Working with Australia's leading cancer institutes, researchers, clinicians, industry partners, advocacy groups and government, we are accelerating molecular profiling, biomarker-led clinical trials, personalised cancer risk management and real-world evidence. About PrOSPeCT PrOSPeCT is Australia's largest precision oncology initiative. Delivered by Omico and a national network of healthcare, research and industry partners, it provides eligible Australians with access to molecular profiling and matching to biomarker-led clinical trials and therapies (at no cost to the patient), while generating clinical, genomic, treatment and outcomes data to advance research, improve cancer care and inform future health policy. Fortrea Contacts: Galen Wilson (Media) - 703-298-0802, [email protected] Kate Dillon (Media) - 646-818-9115, [email protected] Tracy Krumme (Investors) - 984-385-6707, [email protected] Omico Contact: Kym Bramich (Communications) - +61 414 795 087, [email protected] This advertisement has not loaded yet. Quick Picks

Fortrea

Project Manager 2 / Senior Project Manager - Oncology & Ophthalmology

About the job